These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 17064826)
1. Epidermal inoculation of Leishmania-antigen by gold bombardment results in a chronic form of leishmaniasis. Weiss R; Scheiblhofer S; Thalhamer J; Bickert T; Richardt U; Fleischer B; Ritter U Vaccine; 2007 Jan; 25(1):25-33. PubMed ID: 17064826 [TBL] [Abstract][Full Text] [Related]
2. CD8 alpha- and Langerin-negative dendritic cells, but not Langerhans cells, act as principal antigen-presenting cells in leishmaniasis. Ritter U; Meissner A; Scheidig C; Körner H Eur J Immunol; 2004 Jun; 34(6):1542-50. PubMed ID: 15162423 [TBL] [Abstract][Full Text] [Related]
3. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice. Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303 [TBL] [Abstract][Full Text] [Related]
4. Murine epidermal Langerhans cells are potent stimulators of an antigen-specific T cell response to Leishmania major, the cause of cutaneous leishmaniasis. Will A; Blank C; Röllinghoff M; Moll H Eur J Immunol; 1992 Jun; 22(6):1341-7. PubMed ID: 1601029 [TBL] [Abstract][Full Text] [Related]
5. Acute cysticercosis favours rapid and more severe lesions caused by Leishmania major and Leishmania mexicana infection, a role for alternatively activated macrophages. Rodríguez-Sosa M; Rivera-Montoya I; Espinoza A; Romero-Grijalva M; López-Flores R; González J; Terrazas LI Cell Immunol; 2006 Aug; 242(2):61-71. PubMed ID: 17118349 [TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal immunization with oligomannose-coated liposome-entrapped soluble leishmanial antigen induces antigen-specific T-helper type immune response in BALB/c mice through uptake by peritoneal macrophages. Shimizu Y; Takagi H; Nakayama T; Yamakami K; Tadakuma T; Yokoyama N; Kojima N Parasite Immunol; 2007 May; 29(5):229-39. PubMed ID: 17430546 [TBL] [Abstract][Full Text] [Related]
7. Spontaneous recovery of pathogenicity by Leishmania major hsp100-/- alters the immune response in mice. Reiling L; Jacobs T; Kroemer M; Gaworski I; Graefe S; Clos J Infect Immun; 2006 Nov; 74(11):6027-36. PubMed ID: 17057085 [TBL] [Abstract][Full Text] [Related]
8. Antigen presentation by epidermal Langerhans cells in experimental cutaneous leishmaniasis. Axelrod O; Klaus S; Frankenburg S Parasite Immunol; 1994 Nov; 16(11):593-8. PubMed ID: 7862465 [TBL] [Abstract][Full Text] [Related]
9. Protection of C3HeB/FeJ mice against Leishmania amazonensis challenge after previous Leishmania major infection. Vanloubbeeck Y; Jones DE Am J Trop Med Hyg; 2004 Oct; 71(4):407-11. PubMed ID: 15516635 [TBL] [Abstract][Full Text] [Related]
10. CXCR3-/- mice mount an efficient Th1 response but fail to control Leishmania major infection. Rosas LE; Barbi J; Lu B; Fujiwara Y; Gerard C; Sanders VM; Satoskar AR Eur J Immunol; 2005 Feb; 35(2):515-23. PubMed ID: 15668916 [TBL] [Abstract][Full Text] [Related]
11. Re-examination of the immunosuppressive mechanisms mediating non-cure of Leishmania infection in mice. Sacks D; Anderson C Immunol Rev; 2004 Oct; 201():225-38. PubMed ID: 15361244 [TBL] [Abstract][Full Text] [Related]
12. Vaccination with plasmacytoid dendritic cells induces protection against infection with Leishmania major in mice. Remer KA; Apetrei C; Schwarz T; Linden C; Moll H Eur J Immunol; 2007 Sep; 37(9):2463-73. PubMed ID: 17705130 [TBL] [Abstract][Full Text] [Related]
13. The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development. Scott P; Artis D; Uzonna J; Zaph C Immunol Rev; 2004 Oct; 201():318-38. PubMed ID: 15361250 [TBL] [Abstract][Full Text] [Related]
14. Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients. Rafati S; Gholami E; Hassani N; Ghaemimanesh F; Taslimi Y; Taheri T; Soong L Vaccine; 2007 May; 25(21):4159-69. PubMed ID: 17395340 [TBL] [Abstract][Full Text] [Related]
15. The role of chemokines and accessory cells in the immunoregulation of cutaneous leishmaniasis. Moll H Behring Inst Mitt; 1997 Mar; (99):73-8. PubMed ID: 9303204 [TBL] [Abstract][Full Text] [Related]
16. Resistance to Leishmania major in mice. Demant P; Lipoldova M; Svobodova M Science; 1996 Nov; 274(5291):1392-3. PubMed ID: 8966604 [No Abstract] [Full Text] [Related]
17. Transitory or long-lasting immunity to Leishmania major infection: the result of immunogenicity and multicomponent properties of histone DNA vaccines. Carrión J; Folgueira C; Alonso C Vaccine; 2008 Feb; 26(9):1155-65. PubMed ID: 18255202 [TBL] [Abstract][Full Text] [Related]
18. Requirements for Th1-dependent immunity against infection with Leishmania major. von Stebut E; Udey MC Microbes Infect; 2004 Oct; 6(12):1102-9. PubMed ID: 15380780 [TBL] [Abstract][Full Text] [Related]
19. The role of mannose receptor during experimental leishmaniasis. Akilov OE; Kasuboski RE; Carter CR; McDowell MA J Leukoc Biol; 2007 May; 81(5):1188-96. PubMed ID: 17261547 [TBL] [Abstract][Full Text] [Related]
20. TLR9 signaling is essential for the innate NK cell response in murine cutaneous leishmaniasis. Liese J; Schleicher U; Bogdan C Eur J Immunol; 2007 Dec; 37(12):3424-34. PubMed ID: 18034422 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]